INTRODUCTION
Prevention or interruption of metastatic disease progression represents an unfilled therapeutic gap in the management of patients with colorectal cancer, the second leading cause of tumor-related mortality in developed nations. 1, 2 Metastasis results from dissemination of select cell clones, exhibiting aberrant migratory and survival abilities, from the primary tumor to distant organs where they establish extra-intestinal colonies and remodel the local parenchyma. 3, 4 Uniformly, this process drastically aggravates the patient outlook and less than 10% of patients with colon cancer metastasis at distant organs survive beyond five year from diagnosis. 1 Effective strategies to reduce mortality and improve patient outcomes include early detection of pre-metastatic disease and timely recognition of metastatic spread. 2 However, reliable pathological markers of metastatic colorectal cancer are scarce, reflected by the genotypic and phenotypic heterogeneity of colon cancer cells and the variability in analytical methods employed. [3] [4] [5] Moreover, despite the progress of current chemotherapeutic regimens, advanced colorectal cancer with distant metastatic deposits remains incurable. [6] [7] [8] Thus, identification of novel, selective prognostic indicators and therapeutic targets of metastatic disease progression are of paramount importance to reduce morbidity and mortality from colorectal cancer.
Matrix metalloproteinases (MMPs) are zinc-dependent metalloendopeptidases which mediate metastasis. 9, 10 Cancer cells employ MMPs to cleave the extracellular matrix and invade surrounding tissues. 10, 11 Specifically, in colon cancer MMP-9 has emerged as a critical pro-metastatic protease regulating tumor cell growth, mobility and survival. 8, 11, 12 A complex interplay between MMP-9 activity, dynamic membrane regions and signaling by adhesion molecules regulates tumor cell migration, invasion and metastasis. [13] [14] [15] Further, MMP-9 promotes tumor neovascularization by specifically activating angiogenic factors at the cancer cell/matrix interface. 16 Consistent with the hypothesis that MMP-9
is a key regulator of the malignant phenotype, colorectal tumors from patients exhibit overexpression of MMP-9 compared to matched normal adjacent tissues. 8, 12 In that context, stromal cells within the primary colorectal tumor are principal MMP-9 producers and may promote invasion and metastasis by cancer cells. 17, 18 However, human colorectal cancer cells also exhibit cell autonomous abilities to synthesize and secrete MMP-9, an effect associated with induction of MMP-9-dependent proteolytic functions at the pericellular space which mediate metastasis. 8 Indeed, tumor epithelial cell MMP-9
promotes extracellular matrix degradation, actin polymerization-driven cell spreading, and hematogenous tumor cell seeding of mouse lungs. 8 In principle, tumor epithelial cell MMP-9 may represent a specific diagnostic and therapeutic target for colorectal cancer metastasis. 8 Obstacles to these clinical applications include the unknown prognostic role of cancer cell MMP-9, the contribution of stroma-derived MMP-9 to cancer cell pathobiology, and the absence of approaches that selectively target MMP-9 functions mediating metastasis. Here, a previously unrecognized potential for colon tumor epithelial cell MMP-9 as a specific and selective biomarker of metastatic disease progression is revealed. Specifically, relative increase of MMP-9 expression in tumor intestinal epithelial, but not stromal, cells compared to matched normal mucosa cells was demonstrated to predict locoregional metastatic propagation and correlate with advanced disease stages. Together, these observations suggest MMP-9 in tumor epithelial cells is a novel prognostic and predictive marker and a potential therapeutic target for patients with colorectal cancer.
METHODS

Clinical specimens
Fresh surgical specimens from 11 patients (Table I) (Figure 2A) . Further, within epithelial or stromal cell populations, MMP-9 expression was increased or decreased in cells purified from tumors compared to matched normal adjacent tissues (Figure 2A) . Importantly, local metastasis to regional lymph nodes occurred only in patients exhibiting increased MMP-9 expression in tumor cells ( Figure 2B) . In contrast, all cancer patients with decreased MMP-9 levels in both epithelial and stromal cells from tumors were node-negative ( Figure 2B ).
RESULTS
Increased MMP-9 expression in colorectal tumor cells is associated with locoregional metastatic dissemination
MMP-9 in tumor epithelial cells is a prognostic indicator of metastatic colorectal cancer
Of significance, 100% of patients (n=5) with relative MMP-9 overexpression in tumor epithelial cells, compared to normal epithelial cells, exhibited lymph node involvement.
Among the different pathologic sub-groups defined by the relative MMP-9 expression in tumors, colorectal cancer patients with tumor epithelial cell MMP-9 overexpression exhibited the highest metastatic tumor burden in regional lymph nodes ( Figure 2B) .
Conversely, only 83% of patients (n=6) with relative MMP-9 overexpression in tumor stromal cells, compared to stromal cells from the adjacent normal mucosa, had nodepositive disease, reflected by low-to-intermediate metastatic involvement (Figure 2B) .
Accordingly, the proportion of patients with relative overexpression of MMP-9 in tumor epithelial, but not stromal, cells increased significantly in higher node-positive stages (N0, 0%; N1, 50%; N2, 100%), as defined employing the tumor node metastasis (TNM) system by the American Joint Committee on Cancer (AJCC) (Figure 3 , left panels). 19 Attribution of an arbitrary score to the TNM-based stage grouping of patients examined (Table II) 
DISCUSSION
The mortality rate for large bowel cancer, ~50%, largely reflects metastatic disease progression, and tumor deposits at distant locations signify unresectable and untreatable disease. 1, 19 Although the final stages are irreversible, formation of metastatic foci of colon cancer cells at extra-intestinal sites is a vulnerable, multi-step process. Thus, for hematogenous metastatic dissemination cancer cells have to detach from surrounding stroma, migrate through tissue boundaries and invade the primary organ, intravasate into blood vessels, embolize and distribute to distant tissues. 4 Following tumor seeding, only select cancer cells with unique abilities to engage productive cell-matrix interactions with the host parenchyma proliferate and form the metastatic niche. 3, 20 Further, to establish enduring metastasis colon cancer cells have to evade local immune anti-tumor defenses, maliciously remodel the host micro-environment, and develop an autonomous vascular network. 4, 21 As a result, metastasis is a highly selective and inefficient process and >99.99% of intravasated tumor cells are eliminated before reaching their final destination. 22 The complexity of the metastatic process, and its attendant rate-limitation associated with disruption of any individual step, is at the basis of the efficacy of postsurgical adjuvant chemotherapy to prolong survival and reduce mortality in patients with early metastatic colorectal cancer, as determined by lymph node involvement in the absence of distant metastases. 23 Current pathologic assessment of regional colorectal cancer metastasis is performed by examining mesenteric nodes in surgical colectomy specimens with traditional hematoxylin-eosin staining. 24 However, accuracy in estimating node tumor burden is hampered by the great variability in nodal harvest, as a result of interpatient anatomic differences, extent of surgical lymphadenectomy and the ability to search for lymph nodes by the pathologist. 25 The unclear number of lymph nodes to analyze and the imperfect sensitivity of histopathology represent other obstacles for appropriate metastatic disease evaluation. 24, 25 Although introduction of newer molecular-based methods of diagnosis selective for the metastatic process has been invoked, 5 Pathologic staging of patients remains the most important prognostic factor for colorectal cancer. 7 Indeed, the survival rate of these patients is inversely correlated with the AJCC/TNM stage (Table II) , and while more than 90% of patients with stage I survive 5
years from the initial diagnosis, less than 60% or 10% of them are still alive when metastasis has spread to regional (stage III) or distant (stage IV) locations, respectively. 1, 19 There is a considerable risk to understage patients with current histological methods of pathologic node evaluation. 5, 25 Specifically, a clear prognostic dis-homogeneity exists for the node-positive stage III group, and various permutations of the N category have been proposed to better stratify colorectal cancer patients with lymph node involvement. 24 Here, relative MMP-9 overexpression in tumor epithelial cells, compared to normal epithelial cells, predicted lymph node involvement and correlated with increased metastatic tumor burden. Importantly, the patient population exhibiting relative increase of tumor epithelial cell MMP-9 was significantly enriched in higher node-positive stages, suggesting that cancer cell MMP-9 overexpression is a novel prognostic factor in colon cancer. Moreover, colorectal cancer group staging is the fundamental predictive factor for patient management. Thus, pre-metastatic disease stages often require surgery alone with curative outcomes, while metastatic stages warrant postsurgical adjuvant chemotherapy with the intent to improve expectancy and quality of life. 6, 7 Careful stratification of node-positive stage III groups, in turn, may represent the key discriminator for directing patients to less (for stage IIIA), intermediate (for stage IIIB) or more (for stage IIIC) aggressive therapeutic regimens. 24 Patients with relative increase of MMP-9 levels in tumor epithelial cells signified advanced disease stages, characterized by significantly higher proportion of regional lymph nodes harboring metastasis compared to patients with a relative decrease in MMP-9 expression.
Thus, MMP-9 overexpression in primary tumor epithelial cells may represent a highly specific molecular marker for both the prognostic and predictive stratification of patients with colorectal cancer.
In colorectal tumors, fibroblasts and inflammatory cells of the stromal compartment are a principal source of MMP-9, which may confer metastatic abilities to neighboring cancer cells. 17, 18 However, examination of pure cell populations from tumors and adjacent normal mucosa of patients with colorectal cancer demonstrated that MMP-9 of epithelial, but not stromal, cells functions as a pathological marker of metastatic disease progression. Accordingly, cancer cell MMP-9 is a critical regulator of the pathobiology underlying colorectal metastasis, selectively promoting migration, invasion and seeding of target organs by tumor cells. 8 Thus beyond stromal cell contribution, MMP-9
produced by tumor epithelial cells may control unique cellular functions mediating metastasis. Precise elucidations of these mechanisms underlying colorectal cancer invasion and metastasis may provide novel, highly selective and effective therapeutic strategies for targeted prevention and treatment of colorectal cancer metastasis.
CONCLUSION
Advanced, metastatic colorectal cancer remains incurable. Accurate patient stratification into defined prognostic and predictive disease stages is essential to improve quality of life, prolong survival and reduce mortality in colorectal cancer. 5, 7, 25 MMP-9 overexpression in tumor epithelial cells is a novel, specific and selective marker for the prognosis and management of patients with colorectal cancer. Further, cancer cell MMP-9 represents a novel predictive factor which may indicate treatment response and targeted therapy selection to prevent and treat metastatic disease progression. If future studies will demonstrate that MMP-9 overexpression in cancer cells is an independent prognostic and predictive factor, translation of these previously undescribed MMP-9 functions into clinical practice have the potential to profoundly impact the management and cure of patients with colorectal cancer. (Table I) . but not stromal, cells exhibit advanced disease stage (middle panels) and increased lymph node tumor burden (right panels). N categories and disease stage scores are specified in Table II and are based on the AJCC/TNM system. 19 
